Skip to content
USPeptideRxLearnApply for an account

Office-use compounding

Anticipatory compounding vs office use: the difference

USPeptideRx EditorialLast reviewed:

Both put compounded preparations on a shelf before any patient is named, which is why they get confused. The difference is what happens next: anticipatory stock stays with the pharmacy and is released only against a prescription order naming a patient, while office-use stock is transferred to a prescriber to administer with no patient named at any point. Section 353a provides for the first in express terms and not for the second.

The short answer

Anticipatory compounding is a pharmacy holding its own stock ahead of orders it expects to receive. Office use is a pharmacy transferring stock to a prescriber for administration with no patient named at all. The first is a timing arrangement inside the pharmacy; the second is a change of custody and of legal footing.

That is the entire distinction, and it decides whether federal law's compounding exemption is available.

What does federal law say about anticipatory compounding?

It provides for it expressly, in a way that keeps the patient-specific requirement intact.

Section 353a(a)(2) of Title 21 permits compounding "in limited quantities before the receipt of a valid prescription order," where that is based on a history of the pharmacist receiving valid prescription orders within an established relationship between the prescriber, the patient and the pharmacist. The preparation exists before the order does. It is still released against an order naming a patient.

Read alongside § 353a(a), which conditions the exemption on the drug being "compounded for an identified individual patient based on the receipt of a valid prescription order," the design becomes clear. The statute relaxes when the work happens. It does not relax whether a patient is named.

What do the state rules say?

The same thing, in the operative clause each of them attaches to the permission.

Georgia's compounding rule permits anticipatory preparation and provides that such stock shall not be dispensed until a valid patient-specific order is received. North Carolina's rule permits it in the same terms and provides that the preparation "shall not be dispensed until the pharmacy receives a valid prescription order for an individual patient." Louisiana requires anticipated-use preparations to be labelled with a reference to the formula, an assigned lot number and an estimated beyond-use date — a pharmacy's own inventory label, not a label for anyone else's shelf.

New Jersey is the clearest illustration because both halves appear in one chapter. Its rules permit anticipatory batching for patients, on a documented history of valid prescriptions generated solely within an established prescriber, patient and pharmacist relationship, with unique batch numbers, documented component lots and expirations, and visual inspection. The same chapter separately provides that compounded preparations for human use shall not be prepared for a licensed prescriber to use in their practice without a patient-specific prescription, except to the extent federal law permits.

How do they differ in practice?

Six ways, and each is checkable against a document.

Anticipatory compoundingOffice use
Who holds the stockThe pharmacyThe prescriber's practice
Federal provisionSection 353a(a)(2), in express termsNo provision under section 353a; section 353b is the pathway written for it
What releases itA prescription order naming an individual patientNothing — it is administered from practice stock
What justifies making itA documented history of orders in an established relationshipThe practice's anticipated use
Whose recordsThe pharmacy's compounding and dispensing recordsBoth sides, and several states impose distinct duties on each
LabelThe pharmacy's own batch identificationWhere a state requires it, an office-use legend — Illinois mandates "For Office Use Only Not for Resale"

Illinois also draws the line in its definition, which is the most explicit of the states we have read. It defines office use as the administration of a non-patient-specific compounded drug to a patient by a practitioner, and then provides that office use "does not include a pharmacy's delivery of a compounded drug to a prescribing practitioner's office pursuant to a valid patient-specific prescription."

Why does the confusion arise?

Because from the practice's side the two can look identical, and one word does the work.

A vial arrives at your office in both cases. In one it was compounded ahead of time and then assigned to your named patient on their prescription; in the other it was never assigned to anyone. The paperwork differs, the pharmacy's authority differs, and in several states the label differs — but the delivery van does not.

That is why "we compound in advance for our prescribers" is an ambiguous sentence rather than a reassuring one. It is true of both arrangements and tells you nothing about which one is on offer. The question that resolves it is simple: at the moment this preparation leaves your pharmacy, is there a patient named on it?

Does either one answer whether you may hold stock?

No. Anticipatory compounding is a description of the pharmacy's practice, not a permission for yours.

Whether your practice may receive and hold non-patient-specific stock is answered by your own state's rules and, where the supplier is a facility registered with FDA as an outsourcing facility under section 503B, by whether that facility holds your state's credential. Those answers differ sharply between states that look similar, which is the subject of the state-by-state office-use guide.

The federal condition underneath both arrangements is set out at the patient-specific prescription requirement, the two entity types are compared at 503A pharmacies and 503B outsourcing facilities, and the practical version of the question for a clinic is answered at can a med spa stock compounded drugs. Each term is also defined on its own, with the rule text behind it, at anticipatory compounding and office use.

If you want your own state's answer and your supplier's credentials checked before you order, you can apply for an account.

What this page does not establish

  • The states read in full from primary sources are Georgia, North Carolina, Ohio, Louisiana, New Jersey, Illinois, Texas, Florida, California, New York, Arizona and Colorado. The rest have not been researched, and nothing here should be extrapolated to them.
  • This page compares two concepts and cites the rule text distinguishing them. It does not establish what any state permits; each state page carries its own verdict, rule text and last-reviewed date.
  • The New Jersey rule text is verified current as of a January 2025 capture and is self-dated May 2024. A later revision has not been ruled out.
  • Educational information, not legal advice. Verify with your own counsel and your state board before you order.
  • Nothing here describes any drug’s safety or effectiveness.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.

  1. [1]21 U.S.C. § 353a — Pharmacy compounding (Cornell LII)
  2. [2]21 U.S.C. § 353b — Outsourcing facilities (Cornell LII)
  3. [3]Ga. Comp. R. & Regs. Chapter 480-11 (Pharmaceutical Compounding)
  4. [4]21 NCAC 46 — North Carolina Board of Pharmacy rules (current chapter PDF; .2801 office use and anticipatory compounding)
  5. [5]N.J.A.C. 13:39 — State Board of Pharmacy, chapter PDF as captured 2025-01-21
  6. [6]LAC 46:LIII — Louisiana Board of Pharmacy regulations (official Division of Administration file)
  7. [7]68 Ill. Adm. Code 1330.640 — Pharmaceutical Compounding Standards
  8. [8]Ohio Rev. Code § 4729.01 — definitions, including the compounding carve-out